Highlights:
ATTRACT trial results a catalyst for advance in management of deep vein thrombosis
SIRT significantly better tolerated than sorafenib, but does not increase overall survival in hepatocellular carcinoma patients
Matthew Callstrom: IO updates
Andrew Holden: PAD trials
Profile: Bob Abraham
(Visited 297 times, 1 visits today)
